Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Insulet $419 million repurchases of convertible senior notes
We advised the agent on the transaction
Visen Pharmaceutical HK$783.3 million IPO
The shares are listed on the HKEX
Insulet $450 million senior notes offering
The high-yield notes are due 2033
Integer Holdings $1 billion convertible senior notes offering
The 1.875% convertible senior notes are due 2030
Nova Biomedical $2.2 billion acquisition by Advanced Instruments
We are advising Nova Biomedical on the transaction
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
Beam Therapeutics $500 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Endo divestiture of International Pharmaceuticals business
We are advising Endo on the transaction
Sycamore Partners up to $23.7 billion acquisition of Walgreens Boots Alliance
We are advising Sycamore Partners on the transaction
Tenaya Therapeutics $52.5 million units offering
The units comprise common stock and warrants